October 1, 2020 05:59 PM EDT
People
R&D

With a po­ten­tial FDA ap­proval loom­ing, G1 Ther­a­peu­tics taps ex-GSK US pres­i­dent Jack Bai­ley as new CEO

Nicole DeFeudis

Editor

There’s nev­er a per­fect time to step down from a lead­er­ship po­si­tion, G1 Ther­a­peu­tics CEO Mark Vel­le­ca said. But to him, this felt like the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times